Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 764 shares, a decrease of 83.4% from the April 15th total of 4,610 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 7,018 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Universe Pharmaceuticals alerts:

Check Out Our Latest Report on Universe Pharmaceuticals

Universe Pharmaceuticals Price Performance

UPC traded up $0.02 on Tuesday, reaching $2.67. The stock had a trading volume of 4,292 shares, compared to its average volume of 13,551. Universe Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $11.00. The firm has a 50-day moving average of $2.83 and a 200-day moving average of $3.56.

Universe Pharmaceuticals (NASDAQ:UPC – Get Free Report) last issued its earnings results on Thursday, January 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The firm had revenue of $8.92 billion during the quarter.

Universe Pharmaceuticals Company Profile

(Get Free Report)

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.

See Also

• Five stocks we like better than Universe Pharmaceuticals
• On Holdings Sets Up for Marathon Rally: New Highs Are Coming
• The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000
• MP Materials Is Quietly Building a Rare Earth Powerhouse
• AI Demand Fuels Strong Q1 Earnings for Constellation Energy

Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.